Abstract Body

Background

Cabotegravir + rilpivirine long-acting (CAB+RPV LA) is the only complete LA regimen indicated for people with HIV who are virologically suppressed (HIV-1 RNA viral load [VL] <50 copies/mL) on a stable antiretroviral regimen. Previous analyses from this cohort showed that 30% of individuals initiating CAB+RPV LA had BMI of ≥30 kg/m2. This analysis assessed baseline characteristics, persistence, maintenance of virologic suppression, and CVF, stratified by BMI at initiation of CAB+RPV LA. 

Methods

Treatment-experienced adults with HIV who initiated CAB+RPV LA with a VL <50 copies/mL between 21JAN2021-31DEC2024 in the OPERA cohort were included in the analysis. Virologic outcomes were assessed among those who received both initiation injections ≤67 days apart and had ≥1 VL through 28FEB2025. Virologic suppression was defined as maintaining all VLs or the last follow-up VL <50 copies/mL, while CVF was defined as either 2 consecutive VLs ≥200 copies/mL or 1 VL ≥200 copies/mL followed by treatment discontinuation. Three groups were evaluated: <30 kg/m2 (non-obese BMI), ≥30 kg/m2 to <40kg/m2(high BMI), and ≥40 kg/m2 (very high BMI).

Results

Among 4,587 adults initiating CAB+RPV LA, 3,025 (66%) had non-obese BMI, 1,179 (26%) had high BMI, 201 (4%) had very high BMI, and 182 (4%) were missing BMI data at regimen initiation. Demographic characteristics differed substantially across groups (table). Nearly half (46%) of the very high BMI group were female, 68% Black, and 20% Hispanic compared to 10% female, 39% Black, and 33% Hispanic in the non-obese BMI group. All three groups were on their prior regimen for a median of over a year (19, 20, and 23 months, respectively). Non-obese and high BMI individuals were more likely to have switched from an integrase-containing regimen (80% and 76%, respectively), compared to very high BMI individuals (66%). Most were on CAB+RPV LA for over a year (median of 16, 16, and 14 months, respectively). Virologic outcomes were comparable across BMI groups: 93-95% had their last VL <50 c/mL and 78-83% had all their VLs <50 c/mL. CVF was rare (1-2%) across all groups.

Conclusions

In this large real-world cohort, virologically suppressed individuals on CAB+RPV LA injections consistently maintained suppression, with rare virologic failure. Despite demographic differences across BMI groups at initiation, virologic control was comparable across all, with both the high and very high BMI groups consistently maintaining high suppression rates. 

Table or Figure